Imunon

Imunon, Inc. is a clinical-stage biotechnology company committed to developing innovative treatments using its proprietary technology platforms. The company focuses mainly on DNA-based therapies and vaccines that trigger the body's natural immune responses, positioning itself as a pivotal player in the immunotherapy and vaccine fields.

Products and Services

IMNN-001: A DNA-based immunotherapy targeting advanced ovarian cancer, currently in Phase II clinical trials.

IMNN-101: A COVID-19 DNA-based booster vaccine candidate, currently in Phase I trials.

TheraPlas: A delivery platform for DNA therapies aimed at solid tumors.

PlaCCine: A platform developed to enhance vaccine development for infectious diseases.

What Makes Imunon, Inc. Special

Imunon, Inc. stands out due to its PLACCINE technology, which facilitates the delivery of nucleic acids to boost immune responses against various pathogens. This innovation could enhance vaccine efficacy and safety, positioning Imunon at the forefront of the evolving immunotherapy landscape.

Five Things You Need to Know

Imunon's IMNN-001 has completed Phase II clinical trials for treating advanced ovarian cancer.

The company operates a manufacturing facility in Huntsville, Alabama, for the clinical-scale production of its drug candidates.

Imunon collaborates with prominent research institutions, enhancing its research scope.

As of the end of 2024, Imunon held $5.9 million in cash and reported substantial doubts about its ability to continue as a going concern.

Imunon's growth strategy includes forming strategic partnerships to accelerate the market entry of its therapeutic candidates.